Sector News

Shake-up at AstraZeneca as two immuno-oncology leaders leave

January 6, 2015
Life sciences
(Reuters) – AstraZeneca has appointed a new leader for its all-important immuno-oncology drug development operation after the departure of the previous head for personal reasons, the British-based drugmaker said on Monday.
 
Rachel Humphrey left the company at the end November and was replaced last month by Robert Iannone, a member of the global medicines development team, a spokeswoman said in response to inquiries. Her departure was not announced at the time.
 
Humphrey’s exit coincides with the loss of another leader in immuno-oncology, albeit from a different part of the firm. Peter Emtage, who was involved in early research at AstraZeneca’s unit MedImmune, was appointed to a senior position at biotech company Intrexon on Dec. 4.
 
AstraZeneca said the two departures were a coincidence and the company’s work in immuno-oncology was proceeding at full steam, with no problems with any programmes. “It’s business as usual,” the spokeswoman said.
 
The drugmaker, which saw off a $118 billion takeover attempt by Pfizer last year, is banking on new cancer medicines to help revive its fortunes.
 
It is also hoping for an imminent boost to its heart drug Brilinta from results of a clinical trial – known as PEGASUS – assessing the medicine’s use in patients who experienced a heart attack 1-3 years ago. That group could more than double the number of patients eligible for Brilinta. (Reporting by Ben Hirschler; Editing by Pravin Char)

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).